Aromatase inhibitors
High-yield Verified · Oct 2026Aromatase inhibitors stop estrogen being made in the tissues that still make it after menopause. Before menopause, the ovary answers by being stimulated.
Nursing view → administration, monitoring and patient teaching
Compare: Estrogen modulators compared — estrogens, SERMs, aromatase inhibitors and GnRH analogs →
Drugs
Mechanism
Aromatase converts androgens (androstenedione and testosterone) to estrogens (estrone and estradiol); in postmenopausal women this peripheral conversion is the main estrogen source. Anastrozole and letrozole are selective nonsteroidal inhibitors that bind noncovalently and can be displaced (letrozole, a reversible inhibitor, binds competitively to the heme of the enzyme’s cytochrome P450 subunit). Exemestane is a steroidal false substrate that binds irreversibly to the active site and inactivates the enzyme. All three lower serum estradiol without meaningful effect on adrenal corticosteroid or aldosterone synthesis.
Aromatase: the last step to estrogen
Aromatase, also called estrogen synthetase, is a member of the cytochrome P450 superfamily. It demethylates 19-carbon androgens to make phenolic 18-carbon estrogens: androstenedione and testosterone become estrone and estradiol. In the ovary, LH drives theca cells to make androgens, which aromatase in the granulosa cells converts to estrogen; the same conversion happens in adipose tissue.
Before menopause the ovary is the main source of estrogen. After menopause the principal source is conversion of adrenal and ovarian androgens by aromatase in peripheral tissues — the adrenal glands, skin, muscle and fat. Breast cancer cells have aromatase activity too, a possible local estrogen source. Blocking the enzyme lowers serum estrogen and slows estrogen-driven proliferation of hormone receptor-positive breast cancer, without a meaningful effect on cortisol or aldosterone, so no corticosteroid replacement is needed.
Displaceable or suicide: two ways to stop the enzyme
Anastrozole and letrozole (stem -rozole) are nonsteroidal inhibitors. They form noncovalent bonds with aromatase and can be displaced by other molecules. Letrozole competes for the heme of the enzyme’s cytochrome P450 subunit and is described as a reversible inhibitor. Letrozole lowers serum estrone, estradiol and estrone sulfate, and anastrozole significantly lowers serum estradiol.
Exemestane (stem -mestane) is a steroidal inactivator, structurally related to the natural substrate androstenedione. The enzyme takes it as a false substrate and processes it to an intermediate that binds irreversibly to the active site — suicide inhibition. Steroidal inhibitors form a covalent bond that permanently inactivates the enzyme.
Why the labels say postmenopausal
Aromatization of adrenal androgens is not a significant source of estradiol before menopause, so anastrozole would not be expected to lower estradiol in a premenopausal woman. Worse, lowering estrogen removes its negative feedback on the pituitary: gonadotropin secretion rises and the ovary is stimulated. Exemestane causes slight rises in LH and FSH through pituitary feedback.
So every breast cancer indication is labeled for postmenopausal women, and the exemestane label states that it is not indicated for breast cancer in premenopausal women. The same ovarian stimulation is put to use off-label: clinicians may use aromatase inhibitors to induce ovulation in the treatment of infertility, and StatPearls lists letrozole for ovulatory dysfunction in PCOS (clomiphene is on the SERMs page).
Tamoxifen and the aromatase inhibitors
Tamoxifen (SERMs page) is the reference point of the aromatase inhibitor labels: exemestane is labeled after two to three years of tamoxifen, letrozole for extended adjuvant treatment after five years of tamoxifen, and both anastrozole and exemestane for advanced disease that progresses after tamoxifen. The two are not combined: tamoxifen lowered anastrozole plasma levels, and in the adjuvant trial the combination gave no efficacy benefit over tamoxifen alone. Tamoxifen also lowers letrozole levels, but letrozole works when started immediately after tamoxifen.
Compared with tamoxifen, anastrozole caused fewer hot flashes, episodes of vaginal bleeding, endometrial cancers, venous clots and ischemic strokes — but more joint disorders, fractures and raised cholesterol, and bone density fell on anastrozole while it rose on tamoxifen. Estrogen-containing therapies are not given with anastrozole or exemestane because they diminish or interfere with the drug’s action.
Comparing the drugs
Aromatase inhibitors compared
| Drug | Type | Labeled breast cancer uses (postmenopausal) | Elimination | Label points |
|---|---|---|---|---|
| Anastrozole (Arimidex) | Nonsteroidal, selective; noncovalent | Adjuvant HR-positive early; first-line advanced or metastatic; advanced after tamoxifen | Mostly hepatic metabolism; half-life about 50 hours | Not with tamoxifen; ischemic events with pre-existing heart disease; carpal tunnel syndrome |
| Letrozole (Femara) | Nonsteroidal, competitive (heme of CYP450); reversible | Adjuvant; extended adjuvant after tamoxifen; first- and second-line advanced | CYP3A4 and CYP2A6 to an inactive metabolite, excreted renally; half-life about 2 days | Contraindicated in pregnancy; dose reduction in cirrhosis; fatigue and dizziness |
| Exemestane (Aromasin) | Steroidal false substrate; irreversible (suicide inhibition) | Adjuvant ER-positive after 2–3 years of tamoxifen; advanced after tamoxifen | CYP3A4 oxidation; half-life about 24 hours | Taken after a meal; strong CYP3A4 inducers lower exposure; not for premenopausal women |
Pharmacokinetics
- Anastrozole
- Rapidly absorbed; food slows but does not reduce absorption. Hepatic metabolism accounts for about 85% of elimination and renal elimination about 10%; mean elimination half-life 50 hours. No dose adjustment in renal impairment or mild-to-moderate hepatic impairment.
- Letrozole
- Rapidly and completely absorbed, unaffected by food. CYP3A4 and CYP2A6 metabolize it to an inactive carbinol metabolite whose glucuronide is excreted in the urine; terminal half-life about 2 days. Cirrhosis with severe hepatic impairment about doubles exposure, so the dose is reduced.
- Exemestane
- A high-fat meal raises its absorption, and it is taken after a meal. Extensively metabolized, with CYP3A4 the principal isoenzyme; mean terminal half-life about 24 hours. Strong CYP3A4 inducers (rifampicin, phenytoin) significantly lower its exposure, and a dose increase is recommended.
Uses & drug choice
- Anastrozole (Arimidex) — adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer; first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown locally advanced or metastatic breast cancer; treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy
- Letrozole (Femara) — adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer; extended adjuvant treatment of early breast cancer in postmenopausal women who have received 5 years of adjuvant tamoxifen therapy; first-line treatment of postmenopausal women with hormone receptor positive or unknown, locally advanced or metastatic breast cancer; treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy
- Exemestane (Aromasin) — adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to exemestane to complete five consecutive years of adjuvant hormonal therapy; treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy
Adverse effects
- Bone loss, osteoporosis, fractures
- Lower circulating estrogen reduces bone mineral density; loss can appear within the first 6 months.
- Arthralgia, joint and tendon disorders
- Estrogen deficiency lowers bone density, and estrogen helps regulate cytokines and pain perception; arthralgia is the commonest reason for stopping.
- Hot flashes, vaginal dryness, dyspareunia
- Estrogen deprivation.
- Raised cholesterol (anastrozole, letrozole); lower HDL (exemestane)
- Reported in the trials; the labels advise considering cholesterol monitoring.
- Fetal harm
- Based on animal findings and the mechanism of action; letrozole in pregnancy has caused spontaneous abortions and birth defects.
Interactions
Contraindications
- Any aromatase inhibitor — hypersensitivity to the drug or its excipients — Labeled contraindication; reactions include anaphylaxis, angioedema and urticaria.
- Letrozole — pregnancy — Labeled contraindication — letrozole can cause fetal harm.
- Anastrozole or exemestane — pregnancy use caution — A warning rather than a listed contraindication: both can cause fetal harm, so effective contraception is advised.
- Exemestane — premenopausal women use caution — Not indicated for breast cancer in premenopausal women, whose main estrogen source is the ovary.
- Estrogen-containing therapies with anastrozole or exemestane use caution — They should not be used together — estrogen may diminish the aromatase inhibitor’s action.
- Anastrozole — pre-existing ischemic heart disease use caution — Ischemic cardiovascular events were more frequent; the label says to consider risks and benefits.
- Letrozole — cirrhosis and severe hepatic impairment use caution — Exposure is about doubled, so a dose reduction is recommended.
High-yield
Practice questions
Q1A 64-year-old woman, 12 years past menopause, has a hormone receptor-positive early breast cancer resected and starts adjuvant anastrozole. She asks where her estrogen comes from now that her ovaries have stopped.
Which estrogen source does anastrozole mainly suppress?
- A.Ovarian granulosa cells responding to FSH
- B.Adrenal synthesis of cortisol and aldosterone
- C.Aromatization of adrenal and ovarian androgens in peripheral tissues such as fat
- D.Estrogen receptors in breast tissue, which it stimulates as a partial agonist
Show answer
C. Aromatization of adrenal and ovarian androgens in peripheral tissues such as fat — After menopause the principal source of circulating estrogen is aromatase in peripheral tissues — adrenal glands, skin, muscle and fat — converting androstenedione and testosterone to estrone and estradiol; anastrozole inhibits that enzyme and significantly lowers serum estradiol. The ovary is the main estrogen source only before menopause. Anastrozole has no detectable effect on the formation of adrenal corticosteroids or aldosterone, so no replacement is needed. It is an enzyme inhibitor, and in animal studies it has no direct estrogenic activity.
Q2A 41-year-old woman with regular menstrual cycles has hormone receptor-positive breast cancer. She has read that anastrozole causes fewer hot flashes and endometrial cancers than tamoxifen and asks to take anastrozole alone instead.
What would most likely happen if she took anastrozole alone?
- A.Her estradiol would fall to postmenopausal levels within a day
- B.She would need glucocorticoid replacement because aromatase also makes cortisol
- C.Her adrenal glands would take over as her main estrogen source
- D.Lower estrogen would reduce pituitary feedback, gonadotropins would rise, and her ovaries would be stimulated
Show answer
D. Lower estrogen would reduce pituitary feedback, gonadotropins would rise, and her ovaries would be stimulated — In premenopausal women, aromatase inhibitors increase gonadotropin secretion because estrogen’s negative feedback on the pituitary falls, and the ovary is stimulated; aromatization of adrenal androgens is not a significant estradiol source before menopause, so anastrozole would not be expected to lower her estradiol, and the adrenal pathway would not become her main source. That is why the breast cancer labels are postmenopausal. Anastrozole does not affect cortisol or aldosterone secretion, so no glucocorticoid replacement is needed.
Q3A 69-year-old woman with ER-positive early breast cancer has taken tamoxifen for 2.5 years and is switched to exemestane. A student asks how exemestane differs from anastrozole at the enzyme.
Which mechanism is specific to exemestane?
- A.Competitive, reversible binding to the heme of aromatase’s cytochrome P450 subunit
- B.A steroidal false substrate converted to an intermediate that binds aromatase irreversibly
- C.Antagonism of estrogen receptors in breast tissue
- D.Suppression of pituitary LH and FSH release
Show answer
B. A steroidal false substrate converted to an intermediate that binds aromatase irreversibly — Exemestane is a steroidal inactivator related to androstenedione: aromatase processes it as a false substrate into an intermediate that binds irreversibly to the active site — suicide inhibition. Competitive heme binding is how letrozole, a nonsteroidal, reversible inhibitor, works. Exemestane does not bind significantly to steroid receptors, apart from a slight affinity for the androgen receptor, so it is not an estrogen receptor antagonist. And it does not suppress gonadotropins — it causes slight rises in LH and FSH through pituitary feedback.
Q4A 58-year-old postmenopausal woman taking anastrozole for hormone receptor-positive early breast cancer is seen by a new oncologist, who proposes adding tamoxifen to strengthen her treatment.
What does the anastrozole label say about this combination?
- A.It is preferred, because tamoxifen raises anastrozole levels
- B.It is needed, because anastrozole alone does not lower estradiol after menopause
- C.It should not be used: tamoxifen lowered anastrozole levels, and the combination added no benefit over tamoxifen alone
- D.It is safe, because anastrozole inhibits the CYP enzymes that clear tamoxifen
Show answer
C. It should not be used: tamoxifen lowered anastrozole levels, and the combination added no benefit over tamoxifen alone — Coadministration reduced anastrozole plasma concentration by 27%, and in the adjuvant trial the combination showed no efficacy benefit over tamoxifen, so tamoxifen should not be given with anastrozole. Anastrozole significantly lowers serum estradiol in postmenopausal women on its own. Coadministration did not change the pharmacokinetics of tamoxifen, and anastrozole is unlikely to affect other drugs through cytochrome P450 inhibition.
Sources
- Arimidex (anastrozole) — FDA label: indications, contraindication, ischemic events, bone, cholesterol, tamoxifen and estrogen interactions, mechanism — FDA / DailyMed
- Femara (letrozole) — FDA label: indications, contraindications, bone, cholesterol, hepatic impairment, fatigue, pregnancy, mechanism — FDA / DailyMed
- Aromasin (exemestane) — FDA label: indications, bone, vitamin D, estrogen, premenopausal use, CYP3A4 inducers, mechanism — FDA / DailyMed
- Aromatase Inhibitors — mechanism, adverse effects, monitoring, off-label uses — StatPearls (NCBI)
- Ovulation Induction Techniques — letrozole as a reversible aromatase inhibitor — StatPearls (NCBI)
- The use of stems in the selection of INN (-rozole, -mestane) — World Health Organization
- Female Infertility — letrozole for ovulatory dysfunction in PCOS — StatPearls (NCBI)
By LearnDrugs
Educational summary for medical students. Always verify against current prescribing information and guidelines. Not medical advice.